Table 2.
Treatment outcomes of ASAQ and AL treatment, per-protocol analysis
| ASAQ | AL | |||||
|---|---|---|---|---|---|---|
| Overall | AA | AS | Overall | AA | AS | |
| Number of patients, N | 129 | 112 | 17 | 133 | 109 | 24 |
| PCR uncorrected responses on day 28 | ||||||
| Lost to follow-up, N (%) | 22 (17.1) | 22 (19.6) | 1 (5.9) | 15 (11.3) | 13 (11.9) | 2 (8.3) |
| Eligible, N (%) | 107 (82.9) | 90 (80.4) | 16 (94.1) | 118 (88.7) | 96 (88.1) | 22 (91.7) |
| Failure, N (%) | 10 (9.4) | 9 (10.0) | 1 (6.2) | 12 (10.2) | 10 (10.4) | 2 (9.1) |
| ETF, N (%) | 0 | 0 | 0 | 0 | 0 | 0 |
| LCF, N (%) | 5 (4.7) | 4 (4.4) | 1 (6.2) | 5 (4.2) | 5 (5.2) | 0 |
| LPF, N (%) | 5 (4.7) | 5 (5.6) | 0 | 7 (5.9) | 5 (5.2) | 2 (9.1) |
| ACPR, N (%) | 97 (90.6) | 81 (90.0) | 15 (93.8) | 106 (89.8) | 86 (89.6) | 20 (90.9) |
| PCR corrected responses on day 28 | ||||||
| Loss of follow up + new infection, N (%) | 30 (23.3) | 28 (25.0) | 2 (11.8) | 23 (17.3) | 20 (18.3) | 3 (12.5) |
| Eligible, N (%) | 99 (76.7) | 84 (75.0) | 15 (88.2) | 110 (82.7) | 89 (81.7) | 21 (87.5) |
| Failure, N (%) | 3 (3.0) | 3 (3.6) | 0 | 4 (3.6) | 3 (3.3) | 1 (4.8) |
| ETF, N (%) | 0 | 0 | 0 | 0 | 0 | 0 |
| ACPR, N (%) | 96 (97.0) | 81 (96.4) | 15 (100) | 106 (96.4) | 86 (96.6) | 20 (95.2) |
| Recrudescence, N | 3 | 3 | 0 | 4 | 3 | 1 |
| New infection, N | 7 | 6 | 1 | 8 | 7 | 1 |
ASAQ artesunate-amodiaquine, AL artemether-lumefantrine, ETF early treatment failure, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response